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Introduction: Knowledge about the current status of the epidermal
growth factor receptor (EGFR) has resulted in an improvement in
the treatment of non-small cell lung cancer. In contrast, small cell
lung cancer (SCLC) continues to frustrate clinicians with its ten-
dency toward early metastasis and chemotherapy resistance. Recent
studies have reported the EGFR mutation and its response to
gefitinib treatment in SCLC. We would like to share our experience
of EGFR studies on SCLC patients.
Methods: Between 2004 and 2009, we prospectively collected 76
specimens from patients with SCLC at the National Taiwan Uni-
versity Hospital, Taiwan. These specimens included 10 computed
tomography-guided biopsy specimens, 17 echo-guided aspiration
specimens, 37 echo-guided biopsy specimens, 1 surgical lobectomy
specimen, and 11 malignant pleural effusion specimens. Molecular
genetic analysis of the specimens was conducted to detect the EGFR
mutation.
Results: Among the 76 SCLC specimens we examined, 2 (2.6%)
tested positive for the EGFR mutation and both were deletions in
exon 19. One patient was administered gefitinib after several lines of
chemotherapy but showed no treatment response. To date, only 11
EGFRmutant-positive SCLC patients, including our 2 patients, have
been reported. Most of these patients were never smokers. The
SCLC harboring EGFR mutation were more likely to be combined
with adenocarcinoma compared with the whole SCLC population.
Conclusions: The EGFR mutation is rare in SCLC patients. Despite
the presence of the EGFR mutation, gefitinib may not be effective in
treating SCLC patients.
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Small cell lung cancer (SCLC) accounts for 15% of all lungcancer cases. Because of its features, such as fast growth,
early metastasis, and easy development of chemotherapy
resistance, the overall 2-year survival rate in the extensive
stage is merely 4.6%, whereas the overall 5-year survival rate
in the limited stage is 10%.1 Its molecular pathogenesis,
although not thoroughly understood, was linked to autocrine-
related cell growth, proto-oncogene activation, and tumor
suppressor gene inactivation. Targeted treatments have been
designed, but responses have been rather disappointing. Since
2004, epidermal growth factor receptor (EGFR) mutations in
non-small cell lung cancer, such as deletions in exon 19 or
L858R, were associated with a dramatic response to EGFR
tyrosine kinase inhibitor (TKI) and improved survival.2 How-
ever, another study failed to demonstrate antitumor activity of
gefitinib on SCLC in both preclinical studies and a subse-
quent clinical trial.3,4 In a phase II study, 2 of 20 SCLC
patients reported stable disease with gefitinib treatment for
more than 90 days, but EGFR status was not evaluated in the
study.4 For further treatment options, detection of EGFR
mutation in unusual SCLC cases, such as cases of female
nonsmokers with peripheral nodular lesions or concomitant
adenocarcinoma, has been suggested.5 Recent case reports
and studies have focused on SCLC patients with the EGFR
mutation, and some have described treatment responsiveness
after EGFR TKI use.6–8 To accumulate more evidence on
potential novel treatment of SCLC, we reported our study
results of EGFR mutation on patients of SCLC and reviewed
relevant literature about EGFR mutation in SCLC.
PATIENTS AND METHODS
Between July 2004 and June 2009, 76 SCLC specimens
were prospectively collected at the National Taiwan University
Hospital, Taiwan. These specimens included 10 computed
tomography (CT)-guided biopsy specimens, 17 echo-guided
aspiration specimens, 37 echo-guided biopsy specimens, 1
surgical lobectomy specimen, and 11 malignant pleural effu-
sion specimens. Tissues were collected at the time of first
diagnosis after receipt of documented informed consent, and
each sample was immediately immersed in RNAlater (Qia-
gen, Valencia, CA). Patients’ clinical data including demo-
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graphic information, clinical staging, and smoking status
were recorded. This study was approved by the Institutional
Review Board of the National Taiwan University Hospital.
The EGFR mutation was assessed with reverse tran-
scription polymerase chain reaction (RT-PCR) and direct
sequencing. Exons 18 to 21, which are the four exons coded
for the tyrosine kinase domain of the EGFR gene, were
amplified with a forward primer (5-AGC-TTG-TGG-AGC-
CTC-TTA-CAC-C-3) and reverse primer (5-GGA-TCG-
GCC-TCT-TCA-TGC-3). Both the forward and reverse se-
quences were analyzed by basic local alignment search tool
for cDNA of the EGFR gene (accession number NM005228),
and the chromatograms were examined manually. Presence
of the EGFR mutation was confirmed by subsequent inde-
pendent RT-PCR and sequencing reactions. An EGFR muta-
tion-positive result was recorded only if the mutation was
identified in both rounds.
RESULTS
Of the 76 examined SCLC specimens, 2 were found to
be EGFR mutation positive. The EGFR mutation rate in
SCLC was 2.6% in our cohort. Three patients were diagnosed
with lung cancer that had combined small and non-small cell
pathology but showed no EGFR mutation. The median age of
the EGFR wild-type patients was 71 years; among the pa-
tients, 64 (86%) were males, 63 (84%) were smokers, and 56
(75%) were in the extensive stage. Of the two patients with
EGFR-mutated tumors, one was a male smoker and the other
was a female never smoker. The diseases of both patients
were at the limited stage. The mutations included two dele-
tions in exon 19: del 2237–2255 insT (del E746-S752 insV)
in one patient and del 2235–2249 (del E746-A750) in the
other.
Case 1
The first patient was a 63-year-old male heavy smoker
who reported a chronic cough with blood-tinged sputum for
over 1 month and body weight loss of 7 kg over 2 months.
Chest radiography showed a left hilar tumor, and chest CT
revealed a mass in the left lower lobe with diffused medias-
tinum lymphadenopathy. He received echo-guided aspiration
and biopsy. Microscopy revealed tumor nests of SCLC pre-
senting with a marked necrotic component. Immunohisto-
chemical stains revealed diffuse positivity of cytokeratin and
synaptophysin (Figure 1). The initial staging was limited
stage. Because the patient refused radiotherapy, chemother-
apy was administered as first-line treatment. He received two
courses of etoposide and cisplatin and was then shifted to
topotecan because of an adverse reaction. Four courses of
topotecan were administered, and a partial response was
obtained. Subsequent radiotherapy of the residual tumor was
performed. Unfortunately, diffuse liver and peritoneal metas-
tases developed 2 months later, and the patient died 10
months after diagnosis.
Case 2
The second patient was a 54-year-old female never
smoker who complained of chest tightness with right axillary
radiation for several months. Chest plain radiography re-
vealed a tumor in the upper right lung. Subsequent chest CT
revealed a right hilar mass and a peripheral tumor in the right
upper lobe. Echo-guided biopsy revealed a soft white speci-
men that contained hyperchromatic tumor cells that displayed
marked necrosis under microscopy. SCLC was confirmed by
immunoreactivity to cytokeratin, synaptophysin, neuron-spe-
cific enolase, and thyroid transcription factor-1 protein. The
patient was diagnosed with limited-stage SCLC. Treatment
was initiated with concurrent chemoradiation therapy with
etoposide and cisplatin, and a partial response was obtained.
Seven months after diagnosis, brain metastasis developed, for
which whole-brain radiotherapy and two courses of topotecan
were administered. Four months later, the patient developed
liver and renal metastasis. Treatment was changed to doxo-
rubicin at that time; however, bone metastases appeared 1
month later. Despite palliative radiotherapy, the patient’s
condition continued to deteriorate. Gefitinib was prescribed
on the basis of the patient’s EGFR mutation status; however,
the disease continued to progress. Treatment was changed
back to oral etoposide 85 days later, and the patient died 17
months after diagnosis.
DISCUSSION
We prospectively collected SCLC tissues and used
RNA to perform RT-PCR and direct sequencing of EGFR
exons 18 to 21. In this study, we found that the EGFR
mutation rate was 2.6% and confirmed the findings of another
report that stated that EGFR mutation was quite rare in
SCLC.8
Between 2005 and 2006, two cases of EGFR mutation-
positive SCLC were reported, and partial responsiveness to
FIGURE 1. The pathology of a male
smoker with epidermal growth factor
receptor mutation-positive small cell
lung cancer (SCLC). A, Tissue from an
echo-guided lung biopsy. Under hema-
toxylin and eosin staining, SCLC
showed characteristic small round oval
cells with scanty cytoplasm and fine
granular nuclear chromatin. Marked
necrotic components and a crushed
effect were noted. B, Strong positive
immunochemical staining with synap-
tophysin.
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gefitinib was noted in one patient.6,7,9 Araki et al. and Oka-
moto et al. reported the case of a 72-year-old female never
smoker who was initially diagnosed with adenocarcinoma by
sputum cytology. Gefitinib treatment was initiated on the
patient’s request. However, a subsequent bronchoscopic bi-
opsy conducted 3 days later yielded a diagnosis of SCLC.
Direct sequencing showed an EGFR mutation with an exon
19 deletion (delE746-A750). Gefitinib treatment showed
amazing responsiveness both in the primary tumor and in the
liver metastasis. The patient died 5 months later because of
cerebral hemorrhage.7,9 Zakowski et al. reported the case of a
45-year-old female never smoker who was diagnosed with
lung adenocarcinoma by bronchoscopic biopsy. Her initial
EGFR status was unknown, but the tumor showed partial
regression after erlotinib treatment. Eighteen months later, a
brain metastasis developed, and the tumor showed no respon-
siveness to gefitinib. A second lung biopsy revealed SCLC
with EGFR exon 19 deletion. Autopsy showed multiple-
organ metastases of SCLC without any adenocarcinoma.6 In
2007, Morinaga et al.10 reported the case of a 46-year-old
Japanese female never smoker who was diagnosed with
sequential adenocarcinoma and SCLC with the same EGFR
mutation. Fukui et al.5 focused on the relationship between
combined SCLC and EGFRmutation and reported the case of
a 62-year-old female never smoker who had the L858R
mutation at both the SCLC and the adenocarcinoma parts. In
2008, a study on 122 SCLC patients described 5 patients
(4%) who harbored the EGFR mutation.8
To date, nine EGFR mutation-positive SCLC cases
have been reported in six published studies.5–10 In this study,
we encountered two new SCLC patients with the EGFR
mutation. The mutations of all reported patients include six
deletions in exon 19, four in L858R, and one in G719A. The
most enchanting question is what are the clinical character-
istics of SCLC patients with EGFRmutations? To answer this
question, we have summarized all 11 cases in Table 1.
These 11 EGFR mutant-positive SCLC patients had
distinct clinicopathologic features of the epidemiologic data
of the SCLC population. The median age was 62 years. The
gender distribution showed female predominance (63%).
TABLE 1. Comparison of SCLC Patients with EGFR Mutation
Patients Author
Age/
Sex
Smoking
Status Diagnosis Specimen
EGFR
Mutation
Treatment/
Response
Tumor
Location Remarks
1 Araki et al.9 and
Okamoto et al.7
72/F Never
smoker
SCLC Lung biopsy Exon 19 del
(delE746-A750)
Gefitiniba/partial
response
Central The patient was initially
diagnosed adenocarcinoma
and treated with gefitinib.
SCLC was noted 3 d
after gefitinib use.
Patient died because of
cerebral hemorrhage
5 mo later.
2 Zakowski et al.6 45/F Never
smoker
SCLC Lung biopsy Exon 19 del
(delL747-P753insQ)
Gefitiniba/
progressed disease
No data The patient was diagnosed
adenocarcinoma and
treated with erlotinib
with partial response for 18
mo before diagnosis
of SCLC.
3 Morinaga et al.10 46/F Never
smoker
SCLC Lung biopsy Exon 19 del
(delE746-A750)
— Peripheral The patient was diagnosed
adenocarcinoma with
disease stabilization to gefitinib
for 10 mo before diagnosis
of SCLC.
4 Fukui et al.5 62/F Never
smoker
Combined SCLC/
adenocarcinoma
Lung resection Exon 21 (L858R)
both pathology
— Peripheral —
5 Tatematsu et al.8 36/F Never
smoker
Combined SCLC/
adenocarcinoma
Lung resection Exon 21 (L858R) — No data The patient was initially
diagnosed adenocarcinoma
with partial response to
gefitinib for unspecified
duration.
6 81/M Smoker SCLC Lung biopsy Exon 18 (G719A) Gefitiniba/partial
response
No data —
7 69/M Smoker Combined SCLC/
adenocarcinoma
Lung biopsy Exon 21 (L858R) — No data —
8 89/F Smoker SCLC Lung biopsy Exon 21 (L858R) — No data —
9 65/M Smoker Combined SCLC/
adenocarcinoma
Lung resection Exon 19 del — No data —
10 This study 63/M Smoker SCLC Lung biopsy Exon19 del (del
E746-S752 insV)
— Central —
11 54/F Never
smoker
SCLC Lung biopsy Exon 19 del (del
E746-A750)
Gefitiniba/progressed
disease
Peripheral —
a Dosage of gefitinib: 250 mg once a day.
EGFR, epidermal growth factor receptor; F, female; M, male; SCLC, small cell lung cancer; del, deletion.
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Smokers comprised only 45% of the group, which was much
lower than previously reported data (74.1–97.5%).1 Radio-
logically, three patients showed peripheral lesions, two
showed central lesions, and the other six were not described
in the original publication. Four patients (patients 4, 5, 7, and
9 in Table 1) had combined SCLC and adenocarcinoma.
Histologically, the incidence of the combined pathology was
higher compared with previous SCLC data (36% versus
1.2%–28%11,12). Four patients (patients 1, 2, 3, and 5 in Table
1) were diagnosed with adenocarcinoma before being diag-
nosed with SCLC. In summary, EGFRmutant-positive SCLC
would probably be more common in never smokers who had
SCLC combined with adenocarcinoma.
The treatment response of EGFR TKI may be better
clarified when we distinguish the 11 patients into 2 groups,
those with EGFR mutant-positive SCLC at the time of diag-
nosis (patients 1, 4, 6, 7, 8, 9, 10, and 11 in Table 1) and those
with EGFR mutant-positive SCLC after gefitinib treatment
(patients 2, 3, and 5 in Table 1). Three of the eight mutant-
positive patients who confirmed at the time of diagnosis
(patients 1, 6, and 11) received gefitinib treatment, which
resulted in two partial regressions (patient 1 with del E746-
A750 and patient 6 with G719A) and one disease progression
(patient 11 with del E746-A750). Among the three patients
with confirmed EGFR mutation and prior gefitinib treatment,
only one patient (patient 2 with del L747-P753insQ) received
gefitinib treatment but experienced disease progression.
In other studies, EGFR mutation was a significant
predictor of survival in patients with adenocarcinoma treated
with gefitinib.2 This result is different from that observed in
SCLC. This response inconsistency may be due to the EGFR
mutation playing only part of the role in SCLC development or
may be related to limited case numbers. If we were able to obtain
repeated tissue proof at the time of recurrence, we might have
further evidence to explain the suboptimal treatment.
Judging by the 11 cases reported so far, the incidence of
EGFR mutation in SCLC is low and may be related to the
distinct clinicopathologic presentation of SCLC, particularly
among never smokers and those with mixed histology. Test-
ing for EGFR mutations in SCLC tumors is generally not
advised; however, it may be considered in cases where the
patient is a never smoker or has mixed histology. Gefitinib
may not be effective for treating SCLC patients despite the
patients having a positive EGFR mutation status.
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